image of AnaptysBio team member
Focused on Patients The Anaptys Team works to transform patient health by delivering innovative immunology therapeutics. The Anaptys team works to transform patient health by delivering innovative immunology therapeutics.
Theresa, working in the Anaptys lab
image of AnaptysBio team members
Anaptys Overview A clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases. We are a clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases.
Sarah and Ben in an Anaptys conference room
image of 3D render of chemical compound
The Anaptys Difference Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance. Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance.
image of AnaptysBio team members
Transparency, Accountability, Humility Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives. Embracing our core values to guide our efforts discovering and developing medicines that transform patient lives.
May and Annie, reviewing a recent Immunology publication
home-slide-2
Scientific Deep Dive Investigational ANB033,
potential pipeline in a product Listen to our Oct. 2025 virtual investor event Investigational ANB033, potential pipeline in a product... listen to our Oct. 2025 virtual investor event See presentation Listen to the webcast

Press Releases

November 10, 2025
  • Anaptys News

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab was safe and well tolerated but did not meet the primary endpoint of mean change from baseline in modified Mayo Score (mMS) or key secondary endpoints of clinical response and clinical remission at Week 12 in the global Phase 2 trial for moderate-to-severe ulcerative colitis (UC). Placebo rates in the trial were within expected historical ranges. Given these results, this UC trial will be discontinued, resulting in at least $10 million in savings.

November 4, 2025
  • Anaptys News

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.

November 4, 2025
  • Anaptys Events

Anaptys Announces Participation in November Investor Conferences

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences

About

Science

Pipeline

Investors

Careers